Pablo Jara Martin· @pablojaramartin · X·· 1 天前评分70
正文 · 原文
Am I the only one at #ESMO26 who thinks FOURLIGHT-1 lacks an appropriate comparator? Why not use everolimus plus endocrine therapy (investigator’s choice) as the control arm, as in evERA? #ESMOAmbassadors @myESMO
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Pablo Jara Martin · x.com